BioAsia 2026 represents a decisive shift toward execution, scale, and global competitiveness, reflecting the rapid evolution of the life sciences ecosystem
The Union Budget makes a clear and timely choice by placing biopharma at the centre of India’s next manufacturing wave
The facility will offer fully equipped wet labs and strategic scientific support for early-stage biotech companies
Acquisition strengthens EY’s Veeva Centers of Excellence, expanding clinical, regulatory, and commercial services for global pharma and biotech companies
Investment includes biotech agreements with Harbour BioMed, Syneron Bio and BioKangtai
Better serving global partners and advancing healthcare innovation
The company will invest approximately €440 million to increase membrane manufacturing capacity in Carrigtwohill and to build a new manufacturing facility at Blarney Business Park, both in Cork, Ireland
Onshore manufacturing facility is expected to be based in Quebec and produce up to 100 million mRNA respiratory vaccine doses annually
The proposed life sciences research and development centre in North of England region of UK will support acceleration of the company’s research in the areas of biotechnology, health and life sciences
Subscribe To Our Newsletter & Stay Updated
